Will the market of surgical anesthetics grow by a straight line in the next 10 years?

According to the 2017 blue book on the development of China's pharmaceutical market, the sales volume of China's pharmaceutical terminal market in 2016 was 1497.5 billion yuan, up 8.3% year on year, and 803.7 billion yuan in the first half of 2017, up 7.8% year on year Under the policies of drug bidding and price reduction, medical cost control, and drug markup cancellation, the annual growth rate of drug terminal market will slow down Although anesthetics are small varieties, they play an important role in clinic According to the data of minenet, in 2016, anesthesia drugs for surgical operations in public hospitals in key cities accounted for 2% of the total market In addition, some data show that the market scale of narcotic drugs in 2015 was 12.159 billion yuan, an increase of 6.4% year on year It is predicted that the domestic market of narcotic drugs will reach 15 billion yuan in 2017   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the growth of domestic surgical anesthesia market slows down There are two types of composition: surgical anesthetics and auxiliary anesthetics In the first 10 years of the new century, with the rapid growth of surgery and the "trend of stent promotion", anesthesia drugs for surgery in China have shown a rapid growth trend According to the data of minenet, from 2006 to 2010, the growth rate of anesthetics used in surgical operations in public hospitals in key cities in China was 29.09% In recent years, with more and more advanced equipment integrated into laparoscopic technology, laparoscopic technology is more common in surgery, and the use of surgical operations and stents is gradually rationalized, which promotes the standardized management of surgical methods It began to develop in the direction of specialization, minimum injury and procedure, which promoted the diversification of anesthesia From 2011 to 2015, the growth rate of anesthetic drugs for surgical operations in public hospitals in key cities decreased to 11.91% In 2016, the growth rate of anesthetic drugs for surgical operations in public hospitals in key cities continued to slow down to 11.09% With the rising trend of the market for anesthetic drugs for surgical operations, the growth rate is gradually slowing down     none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> with the continuous improvement of the national medical security system, the domestic surgical anesthesia drug market has accelerated the process of full coverage of the medical security system The quality and quantity of all kinds of surgical operations have been improved rapidly after the construction of surgical treatment technology and anesthesia departments in key hospitals of large and medium-sized cities in China is basically in line with western countries According to the data of minenet, in 2016, the market of anesthetics in public hospitals in key cities in China reached 2.063 billion yuan, an increase of 11.09% compared with the previous year; 90 pharmaceutical companies competed in this market, among which 12 foreign companies accounted for 50.17% of the market share, and 78 domestic manufacturers accounted for 49.83% of the market share, showing a pattern of balance   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the proportion of top 5 drugs in general anesthesia is over 90% The 2017 edition of the national medical insurance catalogue contains 24 anesthetics, including 14 general anesthetics, including halogenated hydrocarbon sevoflurane, desflurane, enflurane, isoflurane, remifentanil, sufentanil, fentanyl, barbital thiopental, propofol, etomidate, propofol medium and long fat emulsion, hydroxy Sodium butyrate, ketamine, nitrous oxide and other six drugs According to the data of minenet, in 2016, the general anesthesia market of public hospitals in key cities in China reached 1.87billion yuan, an increase of 10.72% over the previous year Top 5 drugs accounted for 93.80%, respectively propofol, sevoflurane, remifentanil, sufentanil and etomidate Propofol is a representative variety of intravenous anesthetics and a leader in anesthetics market In 2016, the market of propofol in public hospitals exceeded 77000000 yuan, with AstraZeneca accounting for 46.47%, fisenyuskabi accounting for 39.30%, Xi'an Libang accounting for 5.02%, Sichuan Guorui accounting for 4.83%, and Guangdong Qingyuan Jiabo accounting for 4.33% It's worth noting that etomidate is a late comer Etomidate is a non barbiturate intravenous sedative and also a commonly used intravenous anesthetic Etomidate is safe for cardiovascular and cerebrovascular diseases and suitable for elderly patients At present, there are two main formulations in the market, etomidate emulsion and water agent Among them, emulsion has a dominant position because of reducing injection pain In 2016, etomidate was used in public hospitals in key cities in China, with an increase of 32.68% over the previous year The overall market of etomidate in China has reached nearly 500 million yuan Etomidate is one of the varieties with high growth rate, with domestic brands taking the leading position In 2016, "Foley" of etomidate emulsion injection in Enhua, Jiangsu province accounted for 82.05%; and "yituoli" of etomidate emulsion for injection in Braun, Germany accounted for 17.93%, while the share of etomidate injection in Hengrui, Jiangsu Province was small     none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> local anesthetics account for 10%, but the growth rate is relatively high In the 2017 edition of the national medical insurance catalogue, 10 local anesthetics are included, including aminobenzoate tetracaine, procaine, chloroprocaine, amide ropivacaine, lidocaine, levobupivacaine, bupivacaine, compound articaine, and other local anesthetics dacronin and capsaicin According to the data of minenet, in 2016, the local anaesthetic market of public hospitals in key cities in China was RMB 196 million, an increase of 17.20% compared with the previous year The top 5 varieties of local anaesthetic market were ropivacaine, compound lidocaine, dacronin, lidocaine and articaine, accounting for 91.26% of the local anaesthetic market Ropivacaine is the leader of local anesthetic market In 2016, ropivacaine was used in public hospitals in key cities of China, with an increase of 17.19% year on year; AstraZeneca accounted for 80.02%, Chenxin for 3.95%, Hengrui for 3.61%, Qilu pharmaceutical for 2.09% and Wilman for 2.06% The price of local anesthetics is low, and the proportion of local anesthetics is not prominent However, with the popularization and application of minimally invasive surgery, gastroscopy, colonoscopy, bronchoscopy, colposcopy and hysteroscopy, the rapid development of cosmetic surgery and dental surgery has promoted the growth of local anesthetic market in domestic surgery       none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the new challenge of anesthesia market On April 26, 2017, China's CFDA approved the registration of sugeng glucose sodium injection, an innovative drug in the field of anesthesia, in China, under the trade name of breityn, which accelerated the competition in the anesthesia market Anesthesia is an important part of surgery and an independent subject The quality of anesthesia is directly related to the success or failure of an operation, and also to a certain extent determines the safety of patients It is very important to promote the scientific and reasonable application of anesthetics At present, intravenous inhalation combined anesthesia is commonly used Intravenous anesthesia has fast onset and stable induction; inhalation anesthesia is easy to manage, and the depth of anesthesia is easy to control Therefore, the proportion of Intravenous Inhalation Combined Anesthesia in clinical anesthesia is increasing, which is also the mainstream of the current anesthesia market With the development of nanotechnology in surgery, in the next 10 years, there may be non-invasive surgery with less harm than minimally invasive surgery, which objectively lights up the market of surgical anesthetics On the other hand, after the drugs with new mechanism of action come into the market and the patients' informed rate increases, the conservative drug treatment rate rises slowly, while the fast-growing operation rate may be inhibited At the same time, after the basic medical insurance carries out the lump sum settlement management according to the cost of a single disease for some diseases, the use of drugs will be rationalized In the selection of anesthesia drugs for surgery, the first consideration will be toxicity, the second is effectiveness and cost performance, so that the growth rate of anesthesia drugs for surgery will continue to slow down, forming a new challenge.